Program
IRAK4 Inhibitor AZD2962
Its studies are led by AstraZeneca.
Furthest: phase 1, since Jul 3, 20251 company-led study, 1 open or runningNext primary completion: Oct 20, 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 11 open or running | phase 1since Jul 3, 2025 | Jul 3, 2025 | Oct 20, 2028phase 1 · NCT07064122 |
Also a collaborator on its studies: Parexel.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 3, 2025First study: phase 1 study in Hereditary Sensory and Autonomic NeuropathiesFirst studyNCT07064122 · 72 planned · United States, Australia, Japan and more
Ahead
- Oct 20, 2028Primary completion: phase 1 study in Hereditary Sensory and Autonomic NeuropathiesNCT07064122
TargetBeta
IRAK4 →read by rule
“An orally bioavailable inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4), ”NCIt, by rule
Other programs on IRAK4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| emavusertibrule | curis-inc | phase 2 | 3 |
| ARD-885rule | artivila-shenzhen-innovation-center-ltd | phase 1 | 1 |
| HPB-092rule | hangzhou-polymed-biopharmaceuticals-inc | phase 1 | 1 |
| SAR447971 | Sanofi | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07064122Hereditary Sensory and Autonomic Neuropathies · United States, Australia, Japan and more | 1 | Recruiting | Oct 20, 2028 | 72 |
How it is read
Names in the registry
- “AZD2962”, 1 entry
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.